Tag: Drug

Categories
Health

This Drug Will get You Excessive, and Is Authorized (Possibly) Throughout the Nation

This Drug Gets You High, and Is Legal (Maybe) Across the Country

Texas has one of the most restrictive medical marijuana laws in the country, allowing prescription-only sales for a handful of conditions.

That didn’t stop Lukas Gilkey, CEO of Hometown Hero CBD in Austin, Texas. His company sells joints, blunts, gummy bears, steamers, and tinctures that provide a recovery high. In fact, business is booming online too, where he is selling to many people in other states with strict marijuana laws.

But Mr. Gilkey says he’s not an outlaw and that he doesn’t sell marijuana, just a close relationship. He offers products with a chemical compound – Delta-8-THC – which is extracted from hemp. Chemically, it is only slightly different from Delta 9, the main psychoactive ingredient in marijuana.

And that little distinction, it turns out, can make a big difference in the eyes of the law. According to federal law, psychoactive Delta 9 is expressly prohibited. However, delta-8 THC from hemp is not a loophole that some business owners claim they can sell in many states where hemp ownership is legal. The number of customers “coming to Delta 8 is staggering,” said Gilkey.

“You have a drug that essentially gets you high but is completely legal,” he added. “The whole thing is weird.”

The Rise of Delta 8 is a case study of how hardworking cannabis entrepreneurs are pulling hemp and marijuana apart to create countless new product lines with different marketing angles. They build brands from a variety of potencies, flavors, and strains of THC, the intoxicating substance in cannabis, and of CBD, the non-intoxicating compound often sold as a health product.

With Delta 8, entrepreneurs also believe they have found a way to exploit the country’s broken and convoluted laws on recreational marijuana use. However, it is not that simple. Federal agencies, including the Drug Enforcement Administration, are still reviewing their options for enforcement and regulation.

“Dealing with Delta-8 THC is in no way without significant legal risk,” said Alex Buscher, a Colorado attorney specializing in cannabis law.

However, cannabis industry experts said Delta 8 sales actually exploded. Delta 8 is “the fastest growing segment” of hemp products, said Ian Laird, CFO of New Leaf Data Services, which tracks the hemp and cannabis market. Estimating consumer sales at least $ 10 million, he added, “Delta 8 really came out of nowhere last year.”

Marijuana and hemp are essentially the same plant, but marijuana has higher concentrations of delta-9 THC – and as a source of poisoning, it has been a primary focus of business and state and federal lawmakers. Delta 8, if discussed at all, was an esoteric, less potent by-product of both plants.

That changed with the 2018 Farm Bill, an enormous federal law that, among other things, legalized the widespread cultivation and distribution of hemp. The law also specifically allowed the sale of the plant’s byproducts – the only exception was Delta 9, which had THC levels high enough to define it as marijuana.

With no mention of Delta 8 in the legislation, entrepreneurs jumped into the void and began extracting and packaging it as a legal edible and smokable alternative.

Exactly what type of high Delta 8 produces depends on who you ask. Some consider it “marijuana light” while others “refer to it as pain relief with less psychoactivity,” said David Downs, executive editor for content at Leafly.com, a popular source of news and information about cannabis.

In both cases, Delta 8 has become “extremely ascending,” Downs said, reflecting what he calls the “Interregnum of Prohibition of Doom,” where consumer demand and entrepreneurship exploit loopholes in rapidly evolving and broken laws.

“We are receiving reports that in prohibited states like Georgia you can go to a rest stop and look at what looks like a cannabis bud in a jar,” Downs said. The bud is hemp sprayed with highly concentrated Delta 8 oil.

Joe Salome owns the Georgia Hemp Company, which began selling Delta 8 locally in October and shipping it nationally – about 25 orders a day, he said. “It has moved out enormously.”

Its website touts Delta 8 as “very similar to its psychoactive brother, THC,” and offers users the same relief from stress and inflammation, “without the same fearful high that some may experience with THC.”

Mr Salome said he didn’t need to buy an expensive government license to sell medical marijuana because he felt protected by the farm bill.

“Everything is fine there,” he said, explaining that it was now legal to “sell all parts of the facility.”

The legal landscape is contradicting at best. Many states are more permissive than the federal government, which considers marijuana an illegal and highly dangerous drug under the Controlled Substances Act. Medical marijuana is legal in 36 states. It is legal for recreational use in 14 states.

But in the blink of an eye, the federal government opened the door to the sale of hemp products under the Agriculture Act, even in states that have not legalized recreational marijuana use. Few states like Idaho ban hemp altogether, but Delta 8 entrepreneurs are finding a receptive market in others.

Mr. Gilkey’s lawyers believe the farm bill is on their side. “Delta 8, when derived from or derived from hemp, is considered hemp,” said Andrea Steel, co-chair of the cannabis group of companies at Coats Rose, a Houston law firm. She stressed that the legality also depends on whether Delta 9 exceeds the legal limits.

Ms. Steel noted that when making a Delta 8 product, it can be difficult, if not impossible, to filter all of the Delta 9 out of hemp.

“Adding another crease,” she said, “a lot of labs don’t have the ability to differentiate between Delta 8 and Delta 9.”

Lisa Pittman, the other co-chair of the cannabis group of companies at Coats Rose, said the Farm Bill authors may not have considered the ramifications of the law in their reading of the subject.

Ms. Pittman said the ultimate question of a product’s legality may depend on other factors, including how the Delta 8 is manufactured and sourced. In particular, the lawyers said the DEA The rule on this topic seems to suggest that Delta 8 could be illegal if it is made “synthetically” rather than organically.

Lawsuits relating to the interpretation of the DEA rule are currently pending.

Mr Gilkey said he paid more than $ 50,000 in legal fees to make sure he wasn’t breaking the law. A US Coast Guard veteran, Mr. Gilkey worked on a boat anti-drug unit outside of San Diego. He “saw some really tough things,” he said, “and wasn’t happy about the war on drugs.”

He ran a shop in Austin that sold e-liquid for vaping machines. Then in 2019 he started his current business selling CBD. Late last spring, he said he was getting calls from customers on Delta 8.

“I said please explain what this is,” he recalled. Mr. Gilkey, whose company supplies products to other retail stores around the country, saw a great opportunity. After checking with the lawyers, he started packing gummies, vape pens, and other full-size products with Delta 8 that he received from a major hemp supplier.

“It’s about to go mainstream,” he said. And it’s just the beginning. “There is a Delta 10 in the works.”

Categories
Health

Roche arthritis drug reduces loss of life in hospitalized sufferers with extreme Covid, Oxford researchers say

Roche arthritis drug reduces death in hospitalized patients with severe Covid, Oxford researchers say

A pharmacist shows a box of tocilizumab, which is used to treat rheumatoid arthritis, in the pharmacy of Cambrai Hospital in France on April 28, 2020.

Pascal Rossignol | Reuters

A drug used to treat people with rheumatoid arthritis appears to reduce the risk of death in hospitalized patients with severe Covid-19, especially when combined with the steroid dexamethasone, Oxford University researchers said Thursday.

Oxford researchers found that the drug tocilizumab, an intravenous drug of A department of the Swiss drug manufacturer Roche also shortened the length of stay for patients in hospitals and reduced the need for a ventilator. The study was part of the recovery study, which has tested a number of potential treatments for Covid-19 since March.

“Previous studies of tocilizumab had shown mixed results and it was unclear which patients might benefit from the treatment,” said Peter Horby, professor at Oxford University and co-investigator for the recovery study, in a statement. “We now know that tocilizumab benefits apply to all COVID patients with low oxygen levels and significant inflammation.”

A total of 2,022 patients were randomly selected to receive tocilizumab, sold under the brand name Actemra, by intravenous infusion and compared to 2,094 patients who were randomly selected to receive standard care alone. The researchers said 82% of patients were also taking a steroid like dexamethasone, another drug that was found to reduce deaths in the sickest Covid-19 patients.

Researchers said 596 patients in the tocilizumab group died within 28 days, compared with 694 patients in the standard care group. That means that for every 25 patients treated with tocilizumab, “an extra life would be saved,” said Oxford researchers.

The drug increased the chances of being discharged from 47% to 54% within 28 days, the researchers said. The benefits have been seen in all patients, including those who need mechanical ventilators in an intensive care unit, they added. In patients who were not given a ventilator prior to the start of the study, tocilizumab reduced the chance of getting invasive mechanical ventilation or death from 38% to 33%, the researchers said.

The researchers said that using tocilizumab in combination with dexamethasone reduced mortality by about a third in patients who require oxygen and by almost half in patients who require a ventilator.

The results of the Oxford study have not yet been published in a peer-reviewed journal.

Public health officials and infectious disease experts say world leaders will need a range of drugs and vaccines to end the pandemic that, according to Johns, will infect more than 107.4 million people in just over a year and has killed at least 2.3 million people at Hopkins University.

In the US, the Food and Drug Administration has approved Gilead Sciences’ antiviral drug Remdesivir for the treatment of Covid-19 patients who are 12 years or older and require hospitalization.

The FDA has approved the use of two monoclonal antibody treatments as well as two vaccines – from Pfizer and Moderna. A third vaccine from Johnson & Johnson is expected to receive FDA approval as early as this month.

The Covid-19 Therapy Randomized Evaluation, or Recovery Study, was launched in March by researchers at Oxford University to find treatments for Covid-19. The study previously showed that hydroxychloroquine, lopinavir ritonavir, azithromycin, and convalescent plasma had no benefits for patients hospitalized with Covid-19.

The study is currently investigating aspirin, the anti-inflammatory drugs baricitinib and colchicine, and Regeneron’s antibody cocktail.

Categories
Business

Novavax says drug is greater than 89% efficient

Novavax says drug is more than 89% effective

Biotech company Novavax announced Thursday that its coronavirus vaccine was more than 89% effective against Covid-19 in its Phase 3 clinical trial conducted in the UK.

The results were based on 62 confirmed Covid-19 infections among the 15,000 participants in the study. The company said 56 cases were seen in the placebo group, up from six cases in the group that received the vaccine. This resulted in an estimated vaccine effectiveness of 89.3%.

The company’s shares rose more than 23% in after-hours trading.

With the results, the company “has the potential to play an important role in solving this global public health crisis,” said Stanley Erck, CEO of Novavax, in a statement. “We look forward to continuing to work with our partners, employees, investigators and regulators around the world to make the vaccine available as soon as possible.”

The study also found that the vaccine against the British variant, also known as B.1.1.7, appeared to be 85.6% effective. A separate Phase 2 study in South Africa showed that the vaccine is nowhere near as effective against a new strain ravaging that country.

The shot was still considered effective in protecting against the virus, but with an effectiveness rate of only 49.4% among 44 Covid-19 cases in South Africa, where 90% of the cases contain the problematic new variant, the company said.

Due to the lower effectiveness against the strain in South Africa, Novavax plans to select a modified version of the vaccine to provide better protection against the new strain “in the coming days”. The modified vaccine is scheduled to be tested in the second quarter of this year.

Novavax is among several companies developing a vaccine against the virus which, according to Johns Hopkins University, infected more than 101 million people worldwide and killed at least 2.2 million people as of Thursday. To date, only two vaccines – from Pfizer and Moderna – have been approved for use in the United States.

In July, as part of the Trump administration’s Operation Warp Speed ​​initiative, the U.S. government announced that it would pay Novavax $ 1.6 billion to develop and manufacture the potential vaccine, with a goal of 100 million doses by early 2021 submit.

It’s unclear whether Thursday’s data will be enough for Novavax to obtain an emergency clearance from the Food and Drug Administration that would allow distribution in the U.S. The company began a late test involving 30,000 people in the US and Mexico late December.

Novavax’s vaccine contains synthesized parts of the surface protein that the coronavirus uses to infect humans. The company said the vaccine was well tolerated, adding that “serious, serious and medically treated adverse events occurred in low levels and were balanced between vaccine and placebo groups”.

In August, the company announced that data from the first phase of the study showed that the vaccine had produced a promising immune response. Participants received two doses of the potential vaccine, approximately 21 days apart, by intramuscular injection. Novavax also said the vaccine was well tolerated and no serious adverse events were reported.

Categories
Health

Eli Lilly Claims Drug Prevents Coronavirus An infection in Nursing Houses

Eli Lilly Claims Drug Prevents Coronavirus Infection in Nursing Homes

An unusual experiment to prevent nursing home employees and residents from being infected with the coronavirus is successful, drug manufacturer Eli Lilly announced on Thursday.

A drug containing monoclonal antibodies – laboratory-bred virus fighters – prevented symptomatic infections in residents who have been exposed to the virus, even in the frail elderly, who are most vulnerable. This is based on preliminary results from a study conducted in collaboration with the National Institutes of Health.

The researchers found an 80 percent reduction in infections in residents who received the drug compared to those who received a placebo and a 60 percent reduction in staff, results that were very statistically meaningful, Eli Lilly said.

The data has not yet been reviewed or published by experts. The company expects to present the results at a future medical meeting and publish them in a peer-reviewed journal, but did not say when.

The study included 965 participants in nursing homes: 666 employees and 299 residents. (The company had hoped more residents would attend, but it proved difficult to enroll. Many had dementia and others were suspicious of intravenous medication.)

There were four deaths from Covid-19 among study participants. All of them were among those living in nursing homes who were given a placebo, not the drug.

The drug Bamlanivimab already has an emergency approval from the Food and Drug Administration, which enables Eli Lilly to make it available to symptomatic patients early in the course of their infection.

However, this study asked if the drug could stop infections before they started. It was an unusual experiment: medical staff rushed to nursing homes in trucks equipped with mobile laboratories as soon as a single infection was found there. Once the workers arrived, they set up temporary infusion centers to administer the drug.

The research ended that weekend with an emergency meeting of the Data Protection and Monitoring Committee, an independent group that oversees the incoming results. The data was strong and convincing enough to bring the placebos to a halt.

Covid19 vaccinations>

Answers to your vaccine questions

If I live in the US, when can I get the vaccine?

While the exact order of vaccine recipients may vary from state to state, most doctors and residents of long-term care facilities will come first. If you want to understand how this decision is made, this article will help.

When can I get back to normal life after vaccination?

Life will only get back to normal once society as a whole receives adequate protection against the coronavirus. Once countries have approved a vaccine, they can only vaccinate a few percent of their citizens in the first few months. The unvaccinated majority remain susceptible to infection. A growing number of coronavirus vaccines show robust protection against disease. However, it is also possible that people spread the virus without knowing they are infected because they have mild symptoms or no symptoms at all. Scientists don’t yet know whether the vaccines will also block the transmission of the coronavirus. Even vaccinated people have to wear masks for the time being, avoid the crowds indoors and so on. Once enough people are vaccinated, it becomes very difficult for the coronavirus to find people at risk to become infected. Depending on how quickly we as a society achieve this goal, life could approach a normal state in autumn 2021.

Do I still have to wear a mask after the vaccination?

Yeah, but not forever. The two vaccines that may be approved this month clearly protect people from contracting Covid-19. However, the clinical trials that produced these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected with the coronavirus can spread it without experiencing a cough or other symptoms. Researchers will study this question intensively when the vaccines are introduced. In the meantime, self-vaccinated people need to think of themselves as potential spreaders.

Will it hurt What are the side effects?

The vaccine against Pfizer and BioNTech, like other typical vaccines, is delivered as a shot in the arm. The injection is no different from the ones you received before. Tens of thousands of people have already received the vaccines, and none of them have reported serious health problems. However, some of them have experienced short-lived symptoms, including pain and flu-like symptoms that usually last a day. It is possible that people will have to plan to take a day off or go to school after the second shot. While these experiences are not pleasant, they are a good sign: they are the result of your own immune system’s encounter with the vaccine and a strong response that ensures lasting immunity.

Will mRNA vaccines change my genes?

No. Moderna and Pfizer vaccines use a genetic molecule to boost the immune system. This molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse with a cell, allowing the molecule to slide inside. The cell uses the mRNA to make proteins from the coronavirus that can stimulate the immune system. At any given point in time, each of our cells can contain hundreds of thousands of mRNA molecules that they produce to make their own proteins. As soon as these proteins are made, our cells use special enzymes to break down the mRNA. The mRNA molecules that our cells make can only survive a few minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a little longer, so the cells can make extra viral proteins and trigger a stronger immune response. However, the mRNA can hold for a few days at most before it is destroyed.

“When I saw the results table, my jaw dropped,” said Dr. Myron Cohen, professor of medicine at the University of North Carolina at Chapel Hill and principal researcher who helped design and conduct the study.

Although the study has ended, Dr. Daniel Skovronsky, Eli Lilly’s chief scientist, said the company would continue to rush to nursing homes on its study network if an outbreak is detected. “Everyone will get the drug,” he said.

Experts who did not take part in the study were delighted, but emphasized that they had not yet seen complete data. “I only see positive results here,” said Dr. Ofer Levy, director of the Precision Vaccination Program at Boston Children’s Hospital. “That’s a win.”

Dr. Kathleen Neuzil, director of the Center for Vaccine Development and Global Health at the University of Maryland Medical School, was also encouraged.

“The mortality effect is remarkable,” she said, adding that the drug should be used more widely to prevent and treat Covid-19, “especially in populations such as nursing home residents who have high mortality rates and may not respond optimally to vaccines . ” ”

Vaccines also protect people from contracting the virus, of course, and nursing home staff and residents were among the first group to be prioritized for the shots. But supplies are inadequate, and many nursing home workers who fear the vaccines have refused to get them.

And after vaccination, it can take six weeks for the body to produce enough antibodies for maximum protection, said Dr. Srilatha Edupuganti, vaccine researcher at Emory University in Atlanta and study researcher.

Treatment with monoclonal antibodies could provide almost equivalent protection immediately, although it does not last as long as the protection offered by a vaccine.

Eli Lilly plans to reach out to the FDA for an emergency clearance to use the drug to help prevent infection in frail elderly populations, especially in nursing homes or long-term care facilities, said Dr. Skovronsky.

Categories
Business

Covid variant present in South Africa ‘might evade’ Eli Lilly’s antibody drug: CEO

Covid variant found in South Africa ‘could evade’ Eli Lilly's antibody drug: CEO

Dave Ricks, chairman and CEO of Eli Lilly, told CNBC on Tuesday that he expected the company’s Covid-19 antibody drug to be effective against the variant of coronavirus found in the UK

However, he said the exposure observed in South Africa is likely to be more of a challenge.

“The South African variant … is cause for concern. It has more dramatic mutations to the spike protein that these antibody drugs target,” Ricks told Squawk Box. “In theory, it could evade our drugs.”

Eli Lilly’s antibody drug was approved for emergency use by the US Food and Drug Administration in November. The drug is aimed at people recently diagnosed with Covid-19 in hopes of preventing the need for hospitalization. Regeneron’s Covid-19 antibody treatment, which President Donald Trump received after contracting the disease, has also received limited approval from the FDA.

According to Ricks, Eli Lilly wants to work with the FDA to quickly test different versions of antibodies to see if they are against virus variants like the one in South Africa.

“We actually have a large library of these antibodies now that are pre-clinical,” said Ricks. “We could think of a very expedited way to study them in a month or two and then approve their use. That seems like a smart thing because this virus is mutating.”

Discovery of variants

Coronavirus variants originally found in the UK and South Africa have received significant attention in recent weeks. They are believed to be more transmissible – but not more deadly – than previous tribes. Even so, a more contagious virus that leads to more infections could continue to weigh on healthcare systems and lead to more deaths.

The discovery of these mutations also coincides with the introduction of Covid-19 vaccines from drug companies such as Pfizer and BioNTech, as well as Moderna. It has led to some questions about whether the vaccines – along with treatments for the disease – would keep their effectiveness.

In a CNBC interview on Monday, Dr. Ugur Sahin, CEO of BioNTech, confident that his vaccine, manufactured in partnership with Pfizer, will work against the strains of the virus found in the UK and South Africa.

Daniel O’Day, CEO of Gilead Sciences, told CNBC it was testing its remdesivir treatment against these new strains, but said Monday the antiviral drug would likely be effective. Antiviral drugs like remdesivir try to prevent the virus from replicating. In contrast, antibodies like Eli Lillys bind to the virus present in the body and try to neutralize it.

There have been no confirmed cases of the variant, which was first discovered in South Africa in America, but according to the Wall Street Journal, it was discovered in countries like Japan, South Korea, and Switzerland. According to the Centers for Disease Control and Prevention, there have been around 70 confirmed cases of the coronavirus variant in the US that were originally found in the UK.

“It seems clear that Lilly’s single antibody, and likely Regeneron’s cocktail, will stop this as well as the normal variant,” said Ricks of the UK-affiliated tribe. “We haven’t done a clinical study of this effect, but we do have pre-clinical data that strongly suggests that it won’t be a problem.”

Use of antibody therapies

After the FDA approved emergency use for their antibody therapies to Eli Lilly and later Regeneron, problems arose with actually delivering the drug, which requires an intravenous infusion, to Covid patients. In mid-December, CNBC reported that between 5% and 20% of the doses delivered had been administered.

That number is “climbing” now, Ricks said on Monday. He pointed to Alabama as a state where the antibodies are widespread. Alabama “basically runs out and refills every week,” he said.

“There are quite a few” from state to state, Ricks admitted. “We want all states to learn from these practices and really be able to use this medicine, as the benefit is that patients, especially seniors, are kept out of the hospital. We know if you are a senior and have Covid-19 and end up in a hospital hospital bed, the prospects are not good. “

Categories
Health

Chugai soars after UK says drug reduces hospital time for Covid sufferers

Chugai soars after UK says drug reduces hospital time for Covid patients

The Chugai Pharmaceutical Co. company logo will be displayed on Monday, August 18, 2014 at the headquarters of Chugai Pharma Manufacturing Co. in Tokyo, Japan.

Kiyoshi Ota | Bloomberg via Getty Images

SINGAPORE – Shares in Japanese drug maker Chugai Pharmaceutical rose sharply in trading Tuesday after the UK government found the drug tocilizumab was effective in reducing the risk of death and hospital stay for Covid patients.

In trading on Tuesday morning, Chugai’s shares rose 16.26%. The stock has since trimmed some of those gains, but is still trading 7% higher. Tuesday was the first trading day of the week for Chugai shares as Japanese markets were closed on Monday for a holiday.

In a press release on Thursday, the UK said the results of a government-funded clinical trial showed that tocilizumab was among two drugs that “reduced the relative risk of death by 24% when given to patients within 24 hours of entering the intensive care unit was administered “.

The press release also states that patients who received the drugs typically used to treat rheumatoid arthritis “left the intensive care unit an average of 7 to 10 days earlier”.

UK Health and Welfare Secretary Matt Hancock said the results were “another milestone in finding a way out of this pandemic”.

The government also said it will start promoting tocilizumab use in patients admitted to the intensive care unit. NHS will also be working with manufacturer Roche to ensure treatment remains available to UK patients.

Tocilizumab, marketed as Actemra or RoActemra, is part of a joint development between Roche and Chugai. Roche is also the majority shareholder in Chugai.

Last week, Prime Minister Boris Johnson put England on hold to contain a variant of Covid-19 that is more contagious than previous strains.

Coronavirus infection rates continue to rise in many parts of the world even as countries start introducing vaccinations. As a result, some governments have reintroduced social distancing restrictions.

To date, the disease has infected at least 90.8 million people and killed more than 1.9 million people worldwide, according to Johns Hopkins University.

Categories
Health

Eli Lilly’s Alzheimer’s Drug Reveals Promise in Small Trial

Eli Lilly's Alzheimer's Drug Shows Promise in Small Trial

In a small clinical trial, an experimental Alzheimer’s drug slowed the rate at which patients lost the ability to think and care for themselves, drug maker Eli Lilly announced on Monday.

The results have not been published in any form and have not been fully reviewed by other researchers. If exactly, it will be the first time a positive result has been found in a so-called phase 2 study, said Dr. Lon S. Schneider, Professor of Psychiatry, Neurology, and Gerontology at the University of Southern California.

Other experimental drugs for Alzheimer’s disease were never tested in phase 2 studies, went straight to larger phase 3 studies, or did not produce positive results. The Phase 3 trials themselves repeatedly had disappointing results.

The two-year study included 272 patients with brain scans that suggest Alzheimer’s disease. Her symptoms ranged from mild to moderate.

The drug donanemab, a monoclonal antibody, attaches to a small portion of the hard plaques in the brain, which are made up of a protein, amyloid, that is characteristic of Alzheimer’s disease. The patients received the drug by infusion every four weeks.

Participants who received the drug had a 32 percent slowdown in the rate of decline compared to those who received a placebo. In six to twelve months, plaques were gone and stayed gone, said Dr. Daniel Skovronsky, scientific director of the company. At this point, the patients were no longer receiving any medication for the duration of the study – they were given a placebo instead.

The small study needs to be replicated, noted Dr. Michael Weiner, a leading Alzheimer’s researcher at the University of California at San Francisco. Even so, “this is big news,” he said. “This gives hope to patients and their families.”

Eli Lilly has not released the relevant data needed for a thorough analysis, said Dr. Cutter. For example, the company only provided percentages describing functional decline among participants, not the actual numbers.

The company will provide this data at a subsequent meeting and in an article in a medical journal, said Dr. Skovronsky. Eli Lilly received the results on Friday and had to report them immediately, he said, as the results may affect Lilly’s stock.

Dr. Schneider, who served on an independent data protection and monitoring body for the study, said he was not allowed to disclose more data than the company provided.

The experiment served as a test for the so-called amyloid hypothesis. The idea is that Alzheimer’s is closely related to amyloid buildup in the brain; If amyloid accumulation can be prevented or reversed, the disease can be prevented or cured.

Drug companies have spent billions of dollars testing anti-amyloid drugs to no avail, leading many experts to believe the hypothesis is wrong – or that the only way to treat Alzheimer’s is to start very early, before clinical ones There are signs of illness.

The Eli Lilly study recruited patients who were not based on symptoms but rather on scans that showed significant buildups of amyloid in their brain. The researchers also looked at a protein, tau, that forms spaghetti-like tangles in the brain after the disease begins.

“We needed mild to moderate entanglement pathology, but not so many entanglements that the disease may no longer be hoped for,” said Dr. Skovronsky.

The primary endpoint or aim of the study was a measurement that combined performance on mental reasoning and memory tests with ratings of participants’ performance in activities of daily living such as dressing and meal preparation.

The main side effect has been seen regularly in patients given experimental monoclonal antibodies to treat Alzheimer’s disease: an accumulation of fluid in the brain. It occurred in nearly 30 percent of patients, said Dr. Skovronsky, but most of them had no symptoms. The effect was seen on brain scans.

During the study, Eli Lilly started a second phase 2 study, Trailblazer 2, in the hope that the initial efforts would produce results. These results are expected in 2023.

Dr. Skovronsky said Eli Lilly will speak to the Food and Drug Administration and regulators in other countries about giving patients access to the drug.

“Sure, the dates are exciting,” he said. “But we have to see what the regulators say.”

For 25 years he has hoped for definitive evidence that the amyloid hypothesis is correct.

“This is what we’ve been waiting for,” said Dr. Skovronsky.

Categories
Health

Covid Affected person Examine Reveals Some Profit From an Arthritis Drug

Covid Patient Study Shows Some Benefit From an Arthritis Drug

Adding an arthritis drug called baricitinib to Covid treatment regimens that contains the antiviral drug remdesivir can cut recovery times by a day or more, especially for those who are seriously ill, according to a study published Friday.

The results of a government-sponsored clinical trial were released more than three weeks after the Food and Drug Administration received an emergency approval for double treatment. Earlier this month, some experts said they were uncomfortable using medication without a chance to review the underlying data backing their performance. Last month, the World Health Organization also recommended rejecting remdesivir for treating Covid patients as there was no evidence of its use.

In previous press releases, limited results were disclosed showing that hospitalized Covid patients treated with baricitinib and remdesivir recovered one day faster than those who received remdesivir alone.

Some questioned the adoption of the combination treatment because baricitinib came at a high price – which could be around $ 1,500 per patient – and also cited side effects like blood clots. Several doctors also wondered if adding baricitinib would be worth it, since steroids like dexamethasone were cheap and widely available. Both baricitinib and dexamethasone are believed to suppress the excessive inflammation that causes many severe cases of Covid.

The new paper, published in the New England Journal of Medicine, adds some granularity to the results and shows that certain subsets of patients benefited far more from the addition of baricitinib than others. The study included more than 1,000 hospital patients with Covid, all of whom received remdesivir. People who were sick enough to need high doses of supplemental oxygen or non-invasive ventilation recovered eight days faster when baricitinib was included in their medication.

In these groups, “I think the data clearly support a role for baricitinib,” said Dr. Boghuma Kabisen Titanji, an infectious disease doctor at Emory University who pioneered early studies of baricitinib against the coronavirus.

Dr. Titanji also noted that the data suggested that certain patients may be less likely to die or need a ventilator when taking baricitinib in addition to remdesivir. However, like those showing faster recovery times, these results were inconsistent among study participants.

Dr. Lauren Henderson, a pediatric rheumatologist at Boston Children’s Hospital, said she was encouraged by the results and the prospect of another option in the coronavirus treatment arsenal.

She and several other experts added that they may still have a tendency to use dexamethasone as a treatment for seriously ill Covid-19 patients who needed respiratory support.

In contrast to baricitinib, studies have shown that dexamethasone inhibits mortality in seriously ill Covid patients. It’s also inexpensive and easy to get hold of, while baricitinib is more of a specialty drug and may pose barriers to the supply chain, said Dr. Erin McCreary, Infectious Disease Pharmacist at the University of Pittsburgh.

New treatments for Covid-19

Things to know about Covid-19 treatment

Confused By The Terms To Treat Covid-19? Let us help:

    • ACE-2: A protein that sits on the surface of certain types of human cells. The coronavirus has to bind to ACE-2 in order to enter cells.
    • Adverse event: A health problem that occurs in volunteers in a clinical trial with a vaccine or drug. An adverse event is not always caused by the treatment tested in the study.
    • Antibody: A protein produced by the immune system that can attach to a pathogen such as the coronavirus and prevent it from infecting cells.
    • Antiviral drug: A drug that affects the ability of a virus to replicate in cells. The first drug approved in the United States for Covid-19, Remdesivir, is antiviral.
    • Approval, Licensing, and Approval for Emergency Use: Medicines, vaccines and medical devices cannot be sold in the US for no profit approval by the Food and Drug Administration, also known as Licensing. After a company submits the results of clinical studies to the FDA for review, the agency decides whether the product is safe and effective. This process usually takes many months. If the country faces an emergency – like a pandemic – a company can file an application instead Emergency approvalthat can be granted much faster.
    • Compassionate Use: A term used to describe treatments given to seriously ill people even though they have not yet been approved for that use by the Food and Drug Administration.
    • Cytokine storm: An overactive immune system reaction that can lead to massive inflammation and tissue damage. Cytokine storms can be responsible for many of the severe cases of Covid-19, and a number of researchers are testing drugs that may calm them down.
    • Interferon: A molecule of the immune system. Certain types of interferons can cause inflammation in the body while others can contain it. Still other types can stimulate cells to strengthen their defenses against viruses. Researchers are investigating whether treating synthetic interferons can help people fight off the coronavirus.
    • Monoclonal Antibodies: Monoclonal antibodies made in a laboratory mimic the natural antibodies made by the immune system. A number of companies have developed these treatments for Covid-19. President Trump received Regeneron’s antibody treatment soon after the disease was diagnosed.
    • Phases 1, 2 and 3 studies: Clinical trials typically take place in three phases. Phase 1 studies typically involve a few dozen people to determine whether a vaccine or drug is safe. In Phase 2 trials that involve hundreds of people, researchers can try different doses and take more measurements of the vaccine’s effects on the immune system. Phase 3 trials, involving thousands or tens of thousands of volunteers, determine the safety and effectiveness of the vaccine or medicine by waiting to see how many people are protected from the disease it is intended to be used against.
    • Placebo: A substance with no therapeutic effect that is widely used in clinical trials. For example, to see if a vaccine can prevent Covid-19, researchers can inject the vaccine into half of their volunteers while the other half are given a placebo with salt water. You can then compare how many people are infected in each group.
    • Post-market surveillance: The surveillance that occurs after a vaccine or drug has been approved and regularly prescribed by doctors. This typically confirms that the treatment is safe. Rarely, side effects are noted in certain groups of people that were overlooked during clinical trials.
    • Preclinical Research: Studies that take place prior to the start of a clinical trial typically include experiments that test a treatment on cells or animals.
    • Test protocol: A series of procedures that must be performed during a clinical trial.
    • Retrospective study: A study that analyzes data collected in the past to determine how effective a treatment is. Retrospective studies can provide useful information, but they are not as definitive as randomized clinical studies.
    • Spike protein: A protein that sits on the surface of coronaviruses. The spike protein binds to the ACE-2 receptor on human cells using a region called the receptor binding domain (RBD). As soon as the protein accumulates, the virus can enter the cell. Many vaccines and monoclonal antibody treatments are designed to stick to the tip.
    • Standard of care: A treatment that is accepted by medical experts as an appropriate method to treat a specific type of disease. Once a standard for treating a disease is established, new experimental treatments are usually tested against it rather than a placebo.

Several experts pointed to another study by the National Institutes of Health that seeks to directly compare two combination treatment regimens: one in which hospital patients receive remdesivir and baricitinib, and one in which remdesivir is paired with dexamethasone. Dr. McCreary also noted the importance of studying patients receiving both baricitinib and dexamethasone “to see if there is any incremental benefit.”

Dr. Andre Kalil, an infectious disease doctor at the University of Nebraska Medical Center and lead researcher on the new paper, noted that while dexamethasone had already become a widely accepted treatment for Covid-19, the steroid still needed further study. He cited “a variety of serious safety issues” with the drug that warranted thorough investigation.

Like other steroids, dexamethasone, which largely reduces inflammation, can be associated with a variety of undesirable side effects, including worsening conditions like diabetes or osteoporosis.